Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Edap Tms SA    EDAP


News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Edap Tms: EDAP Announces Positive Outcome from CPT Panel for HIFU Reimbursement in the U.S.

share with twitter share with LinkedIn share with facebook
share via e-mail
06/11/2019 | 09:16am EDT

(GlobeNewswire) - AMA allocates a new Category 1 CPT code for High Intensity Focused Ultrasound (HIFU)

Definitive CPT code will cover the transrectal ablation of malignant prostate tissue with HIFU including ultrasound guidance

LYON, France, June 10, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in therapeutic ultrasound, today announced that the American Medical Associations (AMA) CPT Editorial Panel, at its May 2019 meeting, accepted EDAPs application to establish a new Category 1 CPT code that will facilitate reimbursement for the ablation of malignant prostate tissue with HIFU technology. The CPT code description selected by the Panel is Ablation of malignant prostate tissue, transrectal, with high intensity focused ultrasound (HIFU) including ultrasound guidance. The code will be included in the next CPT Codebook and be effective on January 1, 2021.

Marc Oczachowski, EDAP's Chief Executive Officer, said, The AMAs acceptance of our request for a Category 1 CPT code is a significant milestone for EDAP in the reimbursement process of HIFU in the U.S. and a major step forward in the recognition of Focal One, which combines HIFU with proprietary ultrasound guidance technology, as a highly differentiated tool for the targeted ablation of prostate tissue. Additionally, we believe the specific reference to malignant tissue, transrectal approach and ultrasound guidance in the code description is clearly favorable to EDAP and its unique and latest HIFU device generation, the Focal One.

Importantly, this Category 1 CPT code now gives us line-of-sight to definitive reimbursement and, we believe, will have a positive impact on both sales and utilization going forward as it sets and gives a long term guaranty on the HIFU use and adoption to all of our prospects and leads. We look forward to specific reimbursement details in mid-2020, while we further grow our sales pipeline in the U.S. and other key territories, Mr. Oczachowski concluded.

The American Urology Association (AUA) and the American Association of Clinical Urologists (AACU) both supported the application and also participated in the AMA Panel to discuss creation of the code for ablation of malignant prostate tissue by HIFU.


A recognized leader in the global therapeutic ultrasound market for almost 40 years,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices,EDAP TMSintroduced the Focal One in 2013 inEuropeand in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existingFDA-cleared Ablatherm Robotic HIFU and Ablatherm Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL),EDAP TMSexclusively utilizes the latest generation of shock wave source in its Sonolith range of ESWL systems. For more information on the Company, please visithttp://www.edap-tms.com, and us.hifu-prostate.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Company ContactBlandine ConfortInvestor Relations / Legal AffairsEDAP TMS SA+33 4 72 15 31 50bconfort@edap-tms.com

Investor ContactJeremy FefferLifeSci Advisors, LLC212-915-2568 jeremy@lifesciadvisors.com

(c) 2019 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EDAP TMS SA
06/11EDAP TMS : EDAP Announces Positive Outcome from CPT Panel for HIFU Reimbursement..
06/10EDAP TMS : EDAP Announces Positive Outcome from CPT Panel for HIFU Reimbursement..
05/15EDAP TMS : Reports 2019 First Quarter Results
05/02EDAP TMS : SA to Announce First Quarter 2019 Financial Results on Wednesday, May..
04/29EDAP TMS SA : EDAP to Showcase Suite of Therapeutic Ultrasound Products During t..
04/01EDAP TMS SA : EDAP Reports Q4 and Full Year 2018 Results
04/01EDAP TMS SA : University of Chicago Medicine Becomes First Hospital in the Midwe..
03/21EDAP TMS SA : EDAP TMS SA to Announce Fourth Quarter and Fiscal Year 2018 Financ..
03/04EDAP TMS SA : HIFU Pioneer Houston Methodist Hospital Acquires EDAP's Next Gener..
02/06EDAP TMS SA : UCI Health Medical Center Becomes First in the U.S. to Treat Patie..
More news
Financials (USD)
Sales 2019 50,4 M
EBIT 2019 2,55 M
Net income 2019 2,64 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 34,1x
P/E ratio 2020 23,8x
Capi. / Sales2019 1,53x
Capi. / Sales2020 1,33x
Capitalization 77,1 M
Duration : Period :
Edap Tms SA Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,75  $
Last Close Price 2,66  $
Spread / Highest target 144%
Spread / Average Target 116%
Spread / Lowest Target 88,0%
EPS Revisions
Sector and Competitors
1st jan.Capitalization (M$)
EDAP TMS SA44.86%0
ILLUMINA0.99%53 458